What question did this study set out to answer?

To molecularly characterize DLBCL PDX models using LymphGen classification for enhanced translational studies.

April 5, 2026

Abstract 7214: LymphGen-based stratification of DLBCL PDX models mirrors clinical tumor complexity

Key Points

To molecularly characterize DLBCL PDX models using LymphGen classification for enhanced translational studies.
Integrated somatic mutations, copy-number alterations, and structural variants to classify lymphoma models using LymphGen 2.0.
Analyzed forty lymphoma models with complete genomic profiling.
Submitted genomic data to LymphGen's online platform for classification.
Successfully categorized models into genomic subtypes including MCD, BN2, N1, EZB, ST2, A53, and hybrids.
Reported that models mirror clinically observed subtype distribution and genomic features.
Demonstrated potential for subtype-aware therapeutic evaluations, particularly for BTK inhibitors and EZH2 therapies.

Abstract

Abstract Diffuse Large B-Cell Lymphoma (DLBCL) is a highly heterogeneous malignancy whose biological diversity is best captured by modern molecular classifications. The Cell of Origin (COO) system divides tumors into Germinal Center B-cell-like (GCB) BN2, characterized by BCL6 translocations N1, marked by NOTCH1 activation; A53, enriched for TP53 loss EZB, defined by EZH2 mutation, BCL2 rearrangement, Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7214.

Abstract 7214: LymphGen-based stratification of DLBCL PDX models mirrors clinical tumor complexity

Key Points

Abstract

Cite This Study